Novel readouts for neuropathic pain models
Supported by:
16 March 2017
Newer in vivo technologies like kinematic motion analysis can add tremendous value to datasets that evaluate the efficacy of novel therapies. Our data suggests that neuropathic pain is a more profound condition than just hypersensitivity or abnormal sensory response. Expanding the examination to include broader endpoints may help understand possible side effects of new drugs.
This webinar reviews standard neuropathic pain models and readouts and will include fine motor kinematic analysis to highlight gait changes.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Drug Discovery, Drug Discovery Processes, Kinetics, Translational Science
Related organisations
Charles River Laboratories
